Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

[1]  G. Lichtenstein.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial , 2008 .

[2]  L. Peyrin-Biroulet,et al.  Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open‐label study , 2007, Alimentary pharmacology & therapeutics.

[3]  P. Rutgeerts,et al.  Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy: Results of the GAIN Study , 2006 .

[4]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[5]  H. Baron,et al.  Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. , 2005, Journal of pediatric gastroenterology and nutrition.

[6]  S. Hanauer,et al.  An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease , 2004, American Journal of Gastroenterology.

[7]  Infliximab maintenance therapy for fistulising Crohn's disease , 2004 .

[8]  L. V. D. van de Putte,et al.  A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[9]  S. Targan,et al.  Tumor necrosis factor: biology and therapeutic inhibitors. , 2000, Gastroenterology.

[10]  F. Breedveld,et al.  Therapeutic monoclonal antibodies , 2000, The Lancet.

[11]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[12]  S. V. van Deventer.  Tumour necrosis factor and Crohn's disease. , 1997, Gut.